Goldman Sachs Added Novartis AG (NVS) To Buy List, GlaxoSmithKline (GSK) To Sell List
More News related to GSK
- GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- Trading Outlook for Advanced Life Sciences Holdings Inc. Issued by InvestorSoup.com
- Antigenics (AGEN) Indicated that Glaxo's malaria Vaccine Phase III Enrolled 5000 Children to Date
- Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
More News related to NVS
- Trading Outlook for Novavax Inc. Issued by InvestorSoup.com
- Crucell NV (CRXL) Up On Renewed Takeover Chatter
- Hapoalim Securities Initiates Coverage on Nektar Therapeutics (NKTR) with a Buy; Ongoing Programs to Help Drive Share Price
- Novartis Champions Renewable Energy With New Vacaville Solar Array
- Trading Radar for 10/22: AT&T (T), McDonalds (MCD), Amazon.com (AMZN), 3M (MMM), Dow Chemical (DOW), UPS (UPS) Report
Goldman Sachs added Novartis AG (NYSE: NVS) to its Conviction Buy List and added GlaxoSmithKline plc (NYSE: GSK) to its Conviction Sell List.
Related Categories
Analyst CommentsStocks Mentioned
+0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
